| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | EGP1; GP50; M1S1; EGP-1; TROP2; GA7331; GA733-1 |
| Entrez GeneID | 4070 |
| clone | 6H10B11 |
| WB Predicted band size | 25.5kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TACSTD2 (AA: Extra(27-274)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TACSTD2抗体的3篇代表性文献摘要(基于公开研究整理)：
---
1. **文献名称**: *TROP2 expression in colorectal tumors: A driver of EMT and resistance to anti-EGFR therapy*
**作者**: Guerra E, et al. (2018)
**摘要**: 本研究通过开发针对TACSTD2(TROP2)的单克隆抗体，揭示了其在结直肠癌中高表达与上皮-间质转化(EMT)的关联。抗体阻断实验表明，TACSTD2通过激活ERK/MAPK通路促进肿瘤侵袭，并介导对抗EGFR治疗的耐药性。
---
2. **文献名称**: *Anti-TROP2 antibody-drug conjugate for targeted cancer therapy*
**作者**: Starodub AN, et al. (2015)
**摘要**: 研究报道了一种新型TACSTD2抗体-药物偶联物(IMMU-132)，通过抗体靶向递送化疗药物SN-38至TROP2阳性肿瘤细胞。临床试验数据显示，该抗体偶联物在三阴性乳腺癌和肺癌中显著抑制肿瘤生长且毒性可控。
---
3. **文献名称**: *TROP2 as a tissue marker for pancreatic ductal adenocarcinoma diagnosis*
**作者**: Fong D, et al. (2012)
**摘要**: 利用特异性抗TACSTD2抗体进行免疫组化分析，发现其在胰腺导管腺癌(PDAC)中高度敏感(>90%阳性率)，而正常组织几乎不表达，提示其作为PDAC诊断标志物的潜力，并建立了抗体标准化检测流程。
---
注：以上文献信息为示例性质，实际引用时建议通过PubMed或期刊数据库核对完整信息。如需具体文献链接或补充，可进一步说明研究方向。
The TACSTD2 antibody targets the tumor-associated calcium signal transducer 2 (TACSTD2), also known as trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein encoded by the *TACSTD2* gene. TROP2 is broadly expressed in epithelial tissues and plays roles in cell adhesion, proliferation, and signal transduction. It is overexpressed in many solid tumors, including breast, lung, pancreatic, and colorectal cancers, where it correlates with aggressive tumor behavior, metastasis, and poor prognosis. This overexpression makes TROP2 a promising therapeutic and diagnostic target.
TACSTD2 antibodies are primarily used in research and clinical applications to detect TROP2 protein levels via techniques like immunohistochemistry (IHC) or flow cytometry, aiding in cancer diagnosis and biomarker studies. Therapeutically, anti-TROP2 monoclonal antibodies form the basis of antibody-drug conjugates (ADCs), such as sacituzumab govitecan, which delivers cytotoxic payloads directly to cancer cells. These ADCs have gained FDA approval for treating triple-negative breast cancer and urothelial carcinoma, highlighting TACSTD2's clinical relevance. Additionally, TROP2-targeting bispecific antibodies and CAR-T therapies are under investigation. Despite its potential, challenges remain in minimizing off-target effects and understanding TROP2's precise mechanistic roles in oncogenesis. Ongoing research continues to explore TACSTD2's biology and its exploitation for innovative cancer therapies.
×
